Substance P

Overview

Substance P (SP) is an 11-amino-acid neuropeptide belonging to the tachykinin family, first detected in 1931 by Ulf von Euler and John Gaddum in extracts of equine brain and intestine. The "P" in its name originally stood for "powder" or "preparation" — the dried acetone extract in which the substance was discovered. It was not until 1971 that its amino acid sequence was determined, and its role as a primary pain neurotransmitter was established over the following decades.

Substance P is one of the most extensively studied neuropeptides in biomedical research, with roles spanning pain perception, inflammation, mood regulation, gastrointestinal function, and immune modulation. Its primary receptor, the neurokinin-1 receptor (NK1R), has been a major pharmaceutical target, and NK1R antagonists have found clinical applications in treating nausea and are being investigated for depression and other conditions.

Structure and Properties

Amino Acid Sequence

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2

• Molecular weight: 1,347.63 g/mol
• Molecular formula: C63H98N18O13S
• C-terminal amidation: Required for full biological activity
• Family: Tachykinin (characterized by the shared C-terminal sequence Phe-X-Gly-Leu-Met-NH2)

The C-terminal region (amino acids 6-11) is essential for NK1 receptor binding, while the N-terminal region modulates receptor selectivity and metabolic stability.

Distribution

Substance P is widely distributed in both the central and peripheral nervous systems:

• CNS: Substantia nigra, hypothalamus, amygdala, dorsal horn of the spinal cord, brainstem nuclei
• PNS: Sensory neurons (C-fibers and A-delta fibers), enteric nervous system
• Non-neuronal sources: Immune cells (macrophages, dendritic cells, lymphocytes), endothelial cells, keratinocytes

The NK1 Receptor

Substance P acts primarily through the neurokinin-1 receptor (NK1R), a G protein-coupled receptor (GPCR) coupled to Gq/11 proteins. NK1R activation triggers:

• Phospholipase C activation and IP3/DAG signaling
• Intracellular calcium mobilization
• NF-kB activation and pro-inflammatory gene expression
• MAP kinase cascade activation
• Nitric oxide synthase activation

NK1R is expressed in the brain, spinal cord, immune cells, endothelial cells, gastrointestinal smooth muscle, and numerous other tissues.

Substance P also has lower affinity for NK2 (primarily activated by neurokinin A) and NK3 (primarily activated by neurokinin B) receptors.

Physiological Roles

Pain Transmission

Substance P is one of the primary neurotransmitters in the pain signaling pathway:

1. Peripheral nociception: Noxious stimuli activate C-fiber and A-delta sensory neurons, which release substance P (along with CGRP) both centrally and peripherally
2. Spinal cord transmission: SP released in the dorsal horn of the spinal cord activates NK1R on second-order neurons, facilitating pain signal transmission to the brain
3. Central sensitization: Sustained SP release contributes to central sensitization — a state of enhanced pain processing where normally innocuous stimuli become painful (allodynia) and painful stimuli are amplified (hyperalgesia)
4. Neurogenic inflammation: Peripheral release from sensory nerve endings causes vasodilation, plasma extravasation, and immune cell recruitment (the "axon reflex")

Inflammation

Substance P is a potent pro-inflammatory mediator:

• Induces mast cell degranulation, releasing histamine and other inflammatory mediators
• Promotes production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) from macrophages and monocytes
• Increases vascular permeability, leading to edema
• Stimulates leukocyte adhesion and migration
• Activates NF-kB transcription factor in multiple cell types
• Promotes angiogenesis

This inflammatory role extends beyond acute injury — substance P has been implicated in chronic inflammatory conditions including inflammatory bowel disease, asthma, rheumatoid arthritis, and psoriasis.

Gastrointestinal Function

The enteric nervous system contains high concentrations of substance P, where it:

• Stimulates smooth muscle contraction (peristalsis)
• Increases intestinal secretion
• Modulates gut immune responses
• Influences gut-brain axis communication

Mood and Emotion

NK1R is expressed in brain regions associated with mood regulation, including the amygdala and hippocampus. Elevated substance P levels have been found in:

• Cerebrospinal fluid of patients with major depression
• Plasma of patients with anxiety disorders
• Brain regions of patients with PTSD

Emesis (Nausea and Vomiting)

Substance P signaling in the brainstem (nucleus tractus solitarius, area postrema) is a key mediator of chemotherapy-induced nausea and vomiting. This discovery led to the development of NK1R antagonists as anti-emetic agents.

Wound Healing

Despite its pro-inflammatory role, substance P contributes positively to wound healing:

• Promotes keratinocyte and fibroblast migration
• Stimulates angiogenesis
• Enhances epithelial cell proliferation
• Modulates immune cell activity at the wound site

Diabetic wounds often show reduced substance P levels, which may contribute to impaired healing.

NK1R Antagonists: Clinical Applications

The pharmaceutical development of NK1R antagonists represents one of the most significant clinical applications arising from substance P research:

Approved NK1R Antagonists

• Aprepitant (Emend) — FDA-approved for prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV)
• Fosaprepitant — IV prodrug of aprepitant for CINV
• Rolapitant (Varubi) — Long-acting NK1R antagonist for CINV
• Netupitant (in combination with palonosetron as Akynzeo) — CINV prevention

NK1R Antagonists in Depression

Multiple pharmaceutical companies pursued NK1R antagonists for depression based on preclinical evidence and early clinical signals. However, Phase III trials largely failed to demonstrate consistent antidepressant efficacy, dampening enthusiasm for this approach. The reasons for this translational failure remain debated and may involve inadequate brain penetration, insufficient receptor occupancy, or the complexity of depression pathophysiology.

Interactions with Other Peptide Systems

KPV and Alpha-MSH

KPV, a tripeptide derived from alpha-melanocyte-stimulating hormone, exerts anti-inflammatory effects that functionally oppose substance P signaling. The melanocortin and tachykinin systems show reciprocal interactions in inflammation and immune regulation.

CGRP

Calcitonin gene-related peptide (CGRP) is co-released with substance P from sensory neurons. CGRP receptor antagonists (gepants) and anti-CGRP antibodies have been successfully developed for migraine treatment.

Opioid Peptides

Endogenous opioid peptides (endorphins, enkephalins) modulate substance P release in the spinal cord, forming a key mechanism of endogenous pain modulation.

Research Considerations

Substance P research illustrates several important principles in peptide research:

• Pleiotropic actions: A single peptide can have diverse, sometimes opposing effects depending on the tissue, receptor expression level, and physiological context
• Dual roles in pathology and healing: Substance P promotes inflammation (pathological in chronic conditions) but also supports wound healing (beneficial in acute injury)
• Translation challenges: Despite compelling preclinical data for NK1R antagonists in depression, clinical translation was largely unsuccessful
• Biomarker vs. mediator: Elevated substance P levels in disease states do not necessarily mean substance P causes the disease — it may be a consequence rather than a driver

Dosing Protocols

As an endogenous neuropeptide, substance P is not typically administered exogenously in clinical practice. It is primarily studied as a mediator of pain transmission, neurogenic inflammation, and emesis, or through receptor-targeted interventions. The therapeutic relevance of substance P biology is realized through NK1 receptor antagonists (aprepitant/Emend, fosaprepitant, netupitant) which are FDA-approved as antiemetics for chemotherapy-induced nausea and vomiting. Substance P itself is used in research settings for pain and inflammation studies.

Degradation and Metabolism

Substance P is rapidly degraded in vivo by several peptidases:

• Neutral endopeptidase (NEP/neprilysin) — The primary degradation enzyme; cleaves substance P at multiple sites
• Angiotensin-converting enzyme (ACE) — Secondary cleavage
• Half-life: Very short (minutes) in plasma and tissues

This rapid degradation limits the duration of substance P signaling and is one reason why its effects are primarily local rather than systemic under normal physiological conditions.